A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
Conditions:   Clear Cell Renal Cell Carcinoma;   Cervical Carcinoma;   Esophageal Carcinoma;   Pancreatic Adenocarcinoma;   Malignant Pleural Mesothelioma Intervention:   Biological: CTX131 Sponsor:   CRISPR Therapeutics AG Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2023 Category: Research Source Type: clinical trials